Date: 2013-03-11
Type of information: Commercialisation agreement
Compound: Vibativ® (telavancin)
Company: Clinigen (UK) Theravance (USA)
Therapeutic area: Infectious diseases
Type agreement: commercialisation
Action mechanism: Vibativ® is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.
Disease: nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable.
Details: Clinigen Group and Theravance have entered into an exclusive commercialization agreement in the European Union (EU) and certain other countries located in Europe for Vibativ® (telavancin) for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen.
Financial terms: Under the terms of the agreement, Theravance has granted Clinigen exclusive commercialization rights to Vibativ® in the EU and certain other European countries (including Switzerland and Norway). In exchange, Theravance will receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of Vibativ®, ranging from 20% to 30%.
Latest news:
